Patent intelligence · US
US 8128930
Anti-ADDL antibodies and uses thereof
Anti-ADDL antibodies and uses thereof
Patent details — US 8128930
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 6, 2012
- Expiration
- Mar 1, 2032
- Applicant
- Northwestern University
- Claims
- 13
- CPC classes
- A61P, A61P25/00, A61P25/28, A61P3/06
Quick answer
US 8128930 (Anti-ADDL antibodies and uses thereof) is held by Northwestern University. Status: granted. Granted Mar 6, 2012. Expires Mar 1, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Northwestern University
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61P, A61P25/00, A61P25/28, A61P3/06, A61P43/00, A61P9/10
More from Northwestern University
Related pharmaceutical patents in our USPTO index.
-
US 12421280
Insulin like growth factor binding protein bioactive peptide fragments
granted -
US 12414995
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
granted -
US 12414981
JNK inhibitors for use in treating and preventing neurodegenerative disorders
granted -
US 12414963
Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin
granted -
US 12415995
Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
granted -
US 12409205
Nanomolecules for the treatment of inflammatory bowel diseases
granted -
US 12410474
Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
granted -
US 12404533
Bioconjugate vaccines' synthesis in prokaryotic cell lysates
granted
Frequently asked questions
What is US patent 8128930?
US 8128930 (Anti-ADDL antibodies and uses thereof) is held by Northwestern University. Status: granted. Granted Mar 6, 2012. Expires Mar 1, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8128930?
Northwestern University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 595 pharmaceutical patents for this assignee.
When does US 8128930 expire?
Our index shows an expiration date of Mar 1, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.